Press

SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US

Feb 17 • 3 min read

SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics…

Bright Minds Biosciences Announces Non-Executive Director Appointment

Feb 17 • 4 min read

Bright Minds Biosciences Inc. (CSE:DRUG | NASDAQ:DRUG) a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the appointment to its board of directors of David Weiner, MD, as a non-executive director. The appointment is effective immediately. “I am delighted to welcome David to the…

Pioneering Delix Therapeutics Study Published in ‘Science’ Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity

Feb 17 • 4 min read

Delix Therapeutics, a neuroscience company developing novel disease-modifying, neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, shared the findings of a new study published today in Science. The groundbreaking paper, authored by Delix Co-founder and Chief Innovation Officer David E. Olson, PhD, reveals the mechanism that causes serotonin and psychoplastogens to activate the 5-HT2A receptor in different ways. The paper,…

Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase

Feb 17 • 4 min read

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW0 | OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the first cohort in its Phase 1 clinical study of an intravenous formulation of AP-188 (“N,N-Dimethyltryptamine” or “DMT”), a known psychedelic compound…

Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders

Feb 17 • 2 min read

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders, held earlier today. A total of 43,610,863 common shares representing 16.6% of the 262,749,836 issued and outstanding common shares of…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441